Metabolic response at repeat PET/CT predicts pathological response to neoadjuvant chemotherapy in oesophageal cancer.
OBJECTIVES: Reports have suggested that a reduction in tumour 18F-fluorodeoxyglucose (FDG) uptake on positron emission tomography (PET) examination during or after neoadjuvant chemotherapy may predict pathological response in oesophageal cancer. Our aim was to determine whether metabolic response pr...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2012
|
| _version_ | 1826275492806787072 |
|---|---|
| author | Gillies, R Middleton, MR Blesing, C Patel, K Warner, N Marshall, R Maynard, N Bradley, K Gleeson, F |
| author_facet | Gillies, R Middleton, MR Blesing, C Patel, K Warner, N Marshall, R Maynard, N Bradley, K Gleeson, F |
| author_sort | Gillies, R |
| collection | OXFORD |
| description | OBJECTIVES: Reports have suggested that a reduction in tumour 18F-fluorodeoxyglucose (FDG) uptake on positron emission tomography (PET) examination during or after neoadjuvant chemotherapy may predict pathological response in oesophageal cancer. Our aim was to determine whether metabolic response predicts pathological response to a standardised neoadjuvant chemotherapy regimen within a prospective clinical trial. METHODS: Consecutive patients staged with potentially curable oesophageal cancer who underwent treatment within a non-randomised clinical trial were included. A standardised chemotherapy regimen (two cycles of oxaliplatin and 5-fluorouracil) was used. PET/CT was performed before chemotherapy and repeated 24-28 days after the start of cycle 2. RESULTS: Forty-eight subjects were included: mean age 65 years; 37 male. Using the median percentage reduction in SUV(max) (42%) to define metabolic response, pathological response was seen in 71% of metabolic responders (17/24) compared with 33% of non-responders (8/24; P = 0.009, sensitivity 68%, specificity 70%). Pathological response was seen in 81% of subjects with a complete metabolic response (13/16) compared with 38% of those with a less than complete response (12/32; P = 0.0042, sensitivity 52%, specificity 87%). There was no significant histology-based effect. CONCLUSIONS: There was a significant association between metabolic response and pathological response; however, accuracy in predicting pathological response was relatively low. |
| first_indexed | 2024-03-06T22:59:32Z |
| format | Journal article |
| id | oxford-uuid:6197f85e-faeb-4810-9e69-c5aec76ff5e5 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T22:59:32Z |
| publishDate | 2012 |
| record_format | dspace |
| spelling | oxford-uuid:6197f85e-faeb-4810-9e69-c5aec76ff5e52022-03-26T18:01:06ZMetabolic response at repeat PET/CT predicts pathological response to neoadjuvant chemotherapy in oesophageal cancer.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:6197f85e-faeb-4810-9e69-c5aec76ff5e5EnglishSymplectic Elements at Oxford2012Gillies, RMiddleton, MRBlesing, CPatel, KWarner, NMarshall, RMaynard, NBradley, KGleeson, FOBJECTIVES: Reports have suggested that a reduction in tumour 18F-fluorodeoxyglucose (FDG) uptake on positron emission tomography (PET) examination during or after neoadjuvant chemotherapy may predict pathological response in oesophageal cancer. Our aim was to determine whether metabolic response predicts pathological response to a standardised neoadjuvant chemotherapy regimen within a prospective clinical trial. METHODS: Consecutive patients staged with potentially curable oesophageal cancer who underwent treatment within a non-randomised clinical trial were included. A standardised chemotherapy regimen (two cycles of oxaliplatin and 5-fluorouracil) was used. PET/CT was performed before chemotherapy and repeated 24-28 days after the start of cycle 2. RESULTS: Forty-eight subjects were included: mean age 65 years; 37 male. Using the median percentage reduction in SUV(max) (42%) to define metabolic response, pathological response was seen in 71% of metabolic responders (17/24) compared with 33% of non-responders (8/24; P = 0.009, sensitivity 68%, specificity 70%). Pathological response was seen in 81% of subjects with a complete metabolic response (13/16) compared with 38% of those with a less than complete response (12/32; P = 0.0042, sensitivity 52%, specificity 87%). There was no significant histology-based effect. CONCLUSIONS: There was a significant association between metabolic response and pathological response; however, accuracy in predicting pathological response was relatively low. |
| spellingShingle | Gillies, R Middleton, MR Blesing, C Patel, K Warner, N Marshall, R Maynard, N Bradley, K Gleeson, F Metabolic response at repeat PET/CT predicts pathological response to neoadjuvant chemotherapy in oesophageal cancer. |
| title | Metabolic response at repeat PET/CT predicts pathological response to neoadjuvant chemotherapy in oesophageal cancer. |
| title_full | Metabolic response at repeat PET/CT predicts pathological response to neoadjuvant chemotherapy in oesophageal cancer. |
| title_fullStr | Metabolic response at repeat PET/CT predicts pathological response to neoadjuvant chemotherapy in oesophageal cancer. |
| title_full_unstemmed | Metabolic response at repeat PET/CT predicts pathological response to neoadjuvant chemotherapy in oesophageal cancer. |
| title_short | Metabolic response at repeat PET/CT predicts pathological response to neoadjuvant chemotherapy in oesophageal cancer. |
| title_sort | metabolic response at repeat pet ct predicts pathological response to neoadjuvant chemotherapy in oesophageal cancer |
| work_keys_str_mv | AT gilliesr metabolicresponseatrepeatpetctpredictspathologicalresponsetoneoadjuvantchemotherapyinoesophagealcancer AT middletonmr metabolicresponseatrepeatpetctpredictspathologicalresponsetoneoadjuvantchemotherapyinoesophagealcancer AT blesingc metabolicresponseatrepeatpetctpredictspathologicalresponsetoneoadjuvantchemotherapyinoesophagealcancer AT patelk metabolicresponseatrepeatpetctpredictspathologicalresponsetoneoadjuvantchemotherapyinoesophagealcancer AT warnern metabolicresponseatrepeatpetctpredictspathologicalresponsetoneoadjuvantchemotherapyinoesophagealcancer AT marshallr metabolicresponseatrepeatpetctpredictspathologicalresponsetoneoadjuvantchemotherapyinoesophagealcancer AT maynardn metabolicresponseatrepeatpetctpredictspathologicalresponsetoneoadjuvantchemotherapyinoesophagealcancer AT bradleyk metabolicresponseatrepeatpetctpredictspathologicalresponsetoneoadjuvantchemotherapyinoesophagealcancer AT gleesonf metabolicresponseatrepeatpetctpredictspathologicalresponsetoneoadjuvantchemotherapyinoesophagealcancer |